DALLAS, TX — February 13, 2002 — Bextra® (valdecoxib), a new COX-2 specific inhibitor, demonstrated effective post-operative pain relief and significantly reduced patient consumption of the opioid analgesic morphine, when administered post-operatively to patients undergoing knee replacement surgery, according to an investigational study presented this week at the annual meeting of the American Academy of Orthopaedic Surgeons (AAOS).
SOURCE: Pharmacia Corporation
לכתבה המלאה נא הקליקו על הקישור
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!